| 3201 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
62 |
| 3202 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
63 |
| 3203 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
71 |
| 3204 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
72 |
| 3205 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
33 |
| 3206 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
3 |
| 3207 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
65 |
| 3208 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
16 |
| 3209 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
66 |
| 3210 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3211 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
71 |
| 3212 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
62 |
| 3213 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
48 |
| 3214 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
62 |
| 3215 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
48 |
| 3216 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
73 |
| 3217 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
69 |
| 3218 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
79 |
| 3219 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
54 |
| 3220 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
44 |
| 3221 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
63 |
| 3222 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
56 |
| 3223 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
65 |
| 3224 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
72 |
| 3225 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
65 |
| 3226 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3227 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
65 |
| 3228 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
70 |
| 3229 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
66 |
| 3230 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
88 |
| 3231 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
67 |
| 3232 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
52 |
| 3233 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
57 |
| 3234 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
62 |
| 3235 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
36 |
| 3236 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
61 |
| 3237 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
11 |
| 3238 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Germany |
61 |
| 3239 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome – Raeb2 |
Hematology |
2022 |
Standard Therapy |
Poland |
62 |
| 3240 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome Rc |
Hematology |
2022 |
Standard Therapy |
Poland |
3 |
| 3241 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome With Excess Blasts 1 |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3242 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome With Excess Blasts 2 |
Hematology |
2022 |
Standard Therapy |
Poland |
67 |
| 3243 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome With Fibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
72 |
| 3244 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
58 |
| 3245 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
69 |
| 3246 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
57 |
| 3247 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3248 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
73 |
| 3249 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
67 |
| 3250 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
66 |
| 3251 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
69 |
| 3252 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
60 |
| 3253 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2022 |
Standard Therapy |
Poland |
69 |
| 3254 |
Apheresis |
Allogeneic |
Myelofibrosis Post Essential Thrombocythemia |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3255 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2022 |
Standard Therapy |
Poland |
58 |
| 3256 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2022 |
Standard Therapy |
Poland |
72 |
| 3257 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2022 |
Standard Therapy |
Poland |
73 |
| 3258 |
Apheresis |
Autologous |
Myeloma |
Hematology |
2022 |
Standard Therapy |
Germany |
54 |
| 3259 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2022 |
Standard Therapy |
Poland |
31 |
| 3260 |
Apheresis |
Allogeneic |
Myeloproliferative Neoplasms With Acute Myeloid Leukemia |
Hematology |
2022 |
Standard Therapy |
Germany |
59 |
| 3261 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
50 |
| 3262 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
37 |
| 3263 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3264 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3265 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
21 |
| 3266 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
38 |
| 3267 |
Apheresis |
Autologous |
Nodular Lymphocyte Predominant Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
31 |
| 3268 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
73 |
| 3269 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
61 |
| 3270 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
53 |
| 3271 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
18 |
| 3272 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
28 |
| 3273 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
55 |
| 3274 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3275 |
Apheresis |
Autologous |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
52 |
| 3276 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3277 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3278 |
Apheresis |
Allogeneic |
Other Immune System |
Hematology |
2022 |
Standard Therapy |
Poland |
46 |
| 3279 |
Apheresis |
Allogeneic |
Other Malignancy |
Hematology |
2022 |
Standard Therapy |
Poland |
72 |
| 3280 |
Apheresis |
Allogeneic |
Peripheral T-Cell Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
32 |
| 3281 |
Apheresis |
Allogeneic |
Plasma Cell Disorder |
Hematology |
2022 |
Standard Therapy |
Poland |
56 |
| 3282 |
Apheresis |
Allogeneic |
Plasma Cell Leukemia |
Hematology |
2022 |
Standard Therapy |
Poland |
58 |
| 3283 |
Apheresis |
Allogeneic |
Post-Essential Thrombocythemia-Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3284 |
Apheresis |
Allogeneic |
Post–Polycythemia Vera Myelofibrosis (Post-Pv Mf) |
Hematology |
2022 |
Standard Therapy |
Poland |
48 |
| 3285 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
65 |
| 3286 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
65 |
| 3287 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
58 |
| 3288 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
39 |
| 3289 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
67 |
| 3290 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
37 |
| 3291 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
69 |
| 3292 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
62 |
| 3293 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
66 |
| 3294 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
70 |
| 3295 |
Apheresis |
Allogeneic |
Primary Refractory T-Cell Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
55 |
| 3296 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2022 |
Standard Therapy |
Poland |
58 |
| 3297 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2022 |
Standard Therapy |
Germany |
51 |
| 3298 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2022 |
Standard Therapy |
Poland |
53 |
| 3299 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2022 |
Standard Therapy |
Poland |
45 |
| 3300 |
Apheresis |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2022 |
Standard Therapy |
Poland |
3 months |